Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Renal Cell 4Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Rectal Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Kidney Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

fludarabine phosphate 36Whole-Body Irradiation 30Cyclophosphamide 30Mycophenolic Acid 28Azacitidine 27Tacrolimus 25Peripheral Blood Stem Cell Transplantation 24Busulfan 22Methotrexate 15Cyclosporine 15Antilymphocyte Serum 14Decitabine 11Cytarabine 11Melphalan 10fludarabine 9Radiotherapy 8Filgrastim 8Granulocyte Colony-Stimulating Factor 7Etoposide 7Cord Blood Stem Cell Transplantation 7thymoglobulin 6Sirolimus 6Rituximab 6Cyclosporins 6Clofarabine 6venetoclax 5merphos 5Sorafenib 4Lenalidomide 4Injections 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Myelomonocytic, Chronic × CB-839 × Clear all
NCT03047993 2024-05-14

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1/2 Completed
28 enrolled 8 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡